Galapagos/€GLPG

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Galapagos

Galapagos NV, abbreviated as GLPG on stock exchanges, is a global biotechnology firm specializing in the discovery and development of small molecule medicines. The company focuses on innovating treatments primarily in the fields of immunology and oncology. Founded in 1999, Galapagos operates out of its headquarters in Belgium and extends its reach across Europe and the United States, aiming to provide transformative therapies for significant unmet medical needs.

Ticker

€GLPG
Sector
Health Care

Primary listing

AEX

Industry

Biotechnology
Headquarters
Mechelen, Belgium

Employees

704

ISIN

BE0003818359
Website
www.glpg.com

Galapagos Metrics

BasicAdvanced
€1.6B
-
-€2.57
-0.06
-

What the Analysts think about Galapagos

Analyst ratings (Buy, Hold, Sell) for Galapagos stock.

Bulls say / Bears say

Galapagos' strategic decision to spin off its innovative medicines unit into a separate publicly traded entity aims to provide clearer business prospects for investors, potentially unlocking shareholder value. (reuters.com)
The spin-off will be well-capitalized with approximately €2.45 billion in cash, providing substantial resources to develop a pipeline of innovative medicines. (reuters.com)
Gilead Sciences Inc., a major partner and shareholder, will maintain a 25% stake in both Galapagos and the new entity, indicating continued confidence and support from a leading industry player. (reuters.com)
Galapagos reported a significant adjusted loss of €2.33 per share for the quarter ended March 31, 2025, missing analyst expectations and indicating financial challenges. (tradingview.com)
Analysts have recently downgraded Galapagos' stock, with a consensus recommendation of 'Reduce' and a 12-month price target of $25.33, reflecting skepticism about the company's near-term prospects. (defenseworld.net)
The planned reorganization is expected to lead to the reduction of around 300 positions in Europe, or around 40% of the group's workforce, which may impact operational efficiency and morale. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

Galapagos Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Galapagos Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €GLPG

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs